Astrazeneca PLC (NYSE:AZN) has tumbled 1.39% during the past week and has dropped 3.87% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.21%. Astrazeneca PLC (NYSE:AZN) has underperformed the index by 4.75% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Astrazeneca PLC (NYSE:AZN): The stock opened at $27.75 on Friday but the bulls could not build on the opening and the stock topped out at $27.75 for the day. The stock traded down to $27.44 during the day, due to lack of any buying support eventually closed down at $27.58 with a loss of -0.18% for the day. The stock had closed at $27.63 on the previous day. The total traded volume was 8,598,610 shares.
The company shares have dropped -17.30% from its 1 Year high price. On Dec 1, 2015, the shares registered one year high at $34.88 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $28.82 and the 200 Day Moving Average price is recorded at $30.27.
Many analysts have stated their opinion on the company shares. Leerink Swann maintains its view on Astrazeneca PLC (NYSE:AZN) according to the research report released by the firm to its investors. The shares have now been rated Market Perform by the stock experts at the ratings house. Leerink Swann lowers the price target from $38 per share to $34 per share on Astrazeneca PLC. The rating by the firm was issued on May 2, 2016. Institutional Investors own 10.33% of Astrazeneca PLC shares.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).